With Consumer Genetic Testing, Buyer Beware
By Editorial,
The Boston Globe
| 09. 30. 2014
Untitled Document
THE ERA OF direct-to-consumer genetic testing means that anyone can pay $99, spit into a plastic vial, and get back a detailed readout on ancestry and risk factors for scores of diseases. At the forefront of this wave is Silicon Valley startup 23andMe, which has collected the DNA of 700,000 members since it was founded in 2006. This flood of data, however, raises a host of ethical questions that neither testing firms nor their customers may anticipate — especially when unwanted information invades customers’ lives.
The Food and Drug Administration moved last year to protect DNA testing consumers from being bombarded with alarming warnings and hard-to-interpret risk assessments about their health that might give rise to unnecessary procedures. Still, the company can provide consumers with the raw data, allowing them to find experts to interpret it for them. That’s a fair compromise: Americans should be able to obtain information about their genetic background; testing firms should be able to present that information with a minimum of hype.
Another source of controversy is 23andMe’s growing genetic database. As...
Related Articles
By Annika Inampudi, Science | 07.10.2025
Before a baby in the United States reaches a few days old, doctors will run biochemical tests on a few drops of their blood to catch certain genetic diseases that need immediate care to prevent brain damage or other serious...
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Elizabeth Dwoskin and Yeganeh Torbati, The Washington Post | 07.16.2025
A group of well-heeled, 30-something women sat down to dinner last spring at a table set with pregnancy-friendly mocktails and orchids, ready to hear a talk about how to optimize their offspring.
Noor Siddiqui, the founder of an embryo-screening start-up...
By Suzanne O'Sullivan, New Scientist | 07.09.2025
Rare diseases are often hard to spot. They can evade detection until irreversible organ damage or disability has already set in. Last month, in the hope of preventing just this type of harm, the UK’s health secretary, Wes Streeting, announced...